Breakthrough in Precision Psychedelic Therapy by Entropy Neurodynamics
Entropy Neurodynamics Limited (ASX: ENP) is a clinical-stage biotechnology company developing advanced psilocin-based therapies for neuropsychiatric and pain-related disorders. Its lead program, TRP-8803, is an intravenous psilocin formulation engineered to deliver rapid onset, precise dose control and a predictable psychedelic experience, addressing key limitations of traditional oral psilocybin. The company recently achieved a major milestone by successfully dosing the first patient in its binge eating disorder (BED) clinical trial, marking the world’s first clinical use of IV-infused psilocin in a neuropsychiatric condition. The study will treat 12 BED patients across two cohorts, with top-line results expected in Q1 CY26. Earlier Phase 2a trials using TRP-8802, an oral psilocybin formulation, demonstrated more than an 80% reduction in binge episodes, supporting the therapeutic potential of psilocin-assisted therapy. Entropy is also advancing programs in fibromyalgia and irritable bowel syndrome, positioning TRP-8803 as a scalable next-generation psychedelic treatment platform.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Breakthrough in Precision Psychedelic Therapy by Entropy Neurodynamics
Entropy Neurodynamics Limited (ASX: ENP) is a clinical-stage biotechnology company developing advanced psilocin-based therapies for neuropsychiatric and pain-related disorders. Its lead program, TRP-8803, is an intravenous psilocin formulation engineered to deliver rapid onset, precise dose control and a predictable psychedelic experience, addressing key limitations of traditional oral psilocybin. The company recently achieved a major milestone by successfully dosing the first patient in its binge eating disorder (BED) clinical trial, marking the world’s first clinical use of IV-infused psilocin in a neuropsychiatric condition. The study will treat 12 BED patients across two cohorts, with top-line results expected in Q1 CY26. Earlier Phase 2a trials using TRP-8802, an oral psilocybin formulation, demonstrated more than an 80% reduction in binge episodes, supporting the therapeutic potential of psilocin-assisted therapy. Entropy is also advancing programs in fibromyalgia and irritable bowel syndrome, positioning TRP-8803 as a scalable next-generation psychedelic treatment platform.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au